Which study is identified as the newest in the treatment of early psychosis?

Which study is identified as the newest in the treatment of early psychosis?

• A. MATRICS study
• B. ENIGMA study
• C. OPUS study
• D. RAISE study

Answer: (D)

Focusing on what advances treatment for early psychosis most recently helps distinguish among these options. The RAISE program—the Recovery After an Initial Schizophrenia Episode—was developed and implemented starting in the late 2000s into the 2010s as a major US initiative to test coordinated specialty care for first-episode psychosis. It emphasizes an integrated, multi-component approach to treatment, including medication management, psychotherapy, family education, and supports for education and employment, with the aim of improving long-term outcomes. In contrast, MATRICS is a standardized cognitive assessment toolkit used to measure cognitive deficits in schizophrenia rather than a treatment trial; OPUS is an earlier Danish early intervention program from around the turn of the century; ENIGMA is an international imaging genetics collaboration focused on brain structure and function, not treatment. Therefore, RAISE is the most recent treatment-focused study among these options.

Focusing on what advances treatment for early psychosis most recently helps distinguish among these options. The RAISE program—the Recovery After an Initial Schizophrenia Episode—was developed and implemented starting in the late 2000s into the 2010s as a major US initiative to test coordinated specialty care for first-episode psychosis. It emphasizes an integrated, multi-component approach to treatment, including medication management, psychotherapy, family education, and supports for education and employment, with the aim of improving long-term outcomes.

In contrast, MATRICS is a standardized cognitive assessment toolkit used to measure cognitive deficits in schizophrenia rather than a treatment trial; OPUS is an earlier Danish early intervention program from around the turn of the century; ENIGMA is an international imaging genetics collaboration focused on brain structure and function, not treatment. Therefore, RAISE is the most recent treatment-focused study among these options.